DOT1 like histone lysine methyltransferaseGenealiases: DOT1 · KMT4 · NDNS
Q-omics provides the consensus-scored DOT1L profile across patient tissues and cancer cell-line models. DOT1L expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DOT1L is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, DOT1L RNA expression shows 20,076 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where DOT1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOT1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOT1L survival associations across molecular data types. DOT1L RNA expression shows survival associations in the most cancer types (29), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOT1L RNA expression–survival associations across cancer types. High DOT1L expression shows unfavorable associations in ACC, MESO, KICH and LIHC, but favorable associations in HNSC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DOT1L RNA expression.
This table summarizes DOT1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DOT1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOT1L shows lower tumor expression in THCA and LUAD and higher tumor expression in LIHC, STAD, UCEC and HNSC. The LIHC box plot shows higher DOT1L RNA expression in tumor versus normal tissue (log2 FC = +1.355, t-test p < 0.001).
This table shows molecular features associated with DOT1L in patient tissues and cancer cell lines. In patient samples, DOT1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DOT1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
